190 related articles for article (PubMed ID: 38378518)
21. Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells.
Dickreuter E; Eke I; Krause M; Borgmann K; van Vugt MA; Cordes N
Oncogene; 2016 Mar; 35(11):1353-62. PubMed ID: 26073085
[TBL] [Abstract][Full Text] [Related]
22. Cetyltrimethylammonium Bromide Attenuates the Mesenchymal Characteristics of Hypopharyngeal Squamous Cell Carcinoma Through Inhibiting the EGFR/PI3K/AKT Signaling Pathway.
Wu TK; Ou YC; Chen YP; Huang FM; Pan YR; Lee CJ
Anticancer Res; 2021 Aug; 41(8):3789-3799. PubMed ID: 34281838
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
[TBL] [Abstract][Full Text] [Related]
24. α integrin targeting for radiosensitization of three-dimensionally grown human head and neck squamous cell carcinoma cells.
Steglich A; Vehlow A; Eke I; Cordes N
Cancer Lett; 2015 Feb; 357(2):542-8. PubMed ID: 25497870
[TBL] [Abstract][Full Text] [Related]
25. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
[TBL] [Abstract][Full Text] [Related]
26. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
[TBL] [Abstract][Full Text] [Related]
27. Long noncoding RNA MYOSLID promotes invasion and metastasis by modulating the partial epithelial-mesenchymal transition program in head and neck squamous cell carcinoma.
Xiong HG; Li H; Xiao Y; Yang QC; Yang LL; Chen L; Bu LL; Zhang WF; Zhang JL; Sun ZJ
J Exp Clin Cancer Res; 2019 Jun; 38(1):278. PubMed ID: 31238980
[TBL] [Abstract][Full Text] [Related]
28. FUT6 inhibits the proliferation, migration, invasion, and EGF-induced EMT of head and neck squamous cell carcinoma (HNSCC) by regulating EGFR/ERK/STAT signaling pathway.
Wang Q; Liao C; Tan Z; Li X; Guan X; Li H; Tian Z; Liu J; An J
Cancer Gene Ther; 2023 Jan; 30(1):182-191. PubMed ID: 36151332
[TBL] [Abstract][Full Text] [Related]
29. Dynamic changes of the EMT spectrum between circulating tumor cells and the tumor microenvironment in human papillomavirus-positive head and neck squamous cell carcinoma.
Ida S; Takahashi H; Tada H; Mito I; Matsuyama T; Chikamatsu K
Oral Oncol; 2023 Feb; 137():106296. PubMed ID: 36571985
[TBL] [Abstract][Full Text] [Related]
30. Nerve growth factor (NGF)-TrkA axis in head and neck squamous cell carcinoma triggers EMT and confers resistance to the EGFR inhibitor erlotinib.
Lin C; Ren Z; Yang X; Yang R; Chen Y; Liu Z; Dai Z; Zhang Y; He Y; Zhang C; Wang X; Cao W; Ji T
Cancer Lett; 2020 Mar; 472():81-96. PubMed ID: 31838083
[TBL] [Abstract][Full Text] [Related]
31. Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines.
Hinz TK; Kleczko EK; Singleton KR; Calhoun J; Marek LA; Kim J; Tan AC; Heasley LE
Mol Pharmacol; 2019 Dec; 96(6):862-870. PubMed ID: 31554698
[TBL] [Abstract][Full Text] [Related]
32. Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer.
Hsu DS; Hwang WL; Yuh CH; Chu CH; Ho YH; Chen PB; Lin HS; Lin HK; Wu SP; Lin CY; Hsu WH; Lan HY; Wang HJ; Tai SK; Hung MC; Yang MH
Clin Cancer Res; 2017 Aug; 23(15):4388-4401. PubMed ID: 28196873
[No Abstract] [Full Text] [Related]
33.
Hu C; Zhou A; Hu X; Xiang Y; Huang M; Huang J; Yang D; Tang Y
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362025
[TBL] [Abstract][Full Text] [Related]
34. Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response.
Korpela SP; Hinz TK; Oweida A; Kim J; Calhoun J; Ferris R; Nemenoff RA; Karam SD; Clambey ET; Heasley LE
J Transl Med; 2021 Jan; 19(1):43. PubMed ID: 33485341
[TBL] [Abstract][Full Text] [Related]
35. Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway.
Maseki S; Ijichi K; Tanaka H; Fujii M; Hasegawa Y; Ogawa T; Murakami S; Kondo E; Nakanishi H
Br J Cancer; 2012 Mar; 106(6):1196-204. PubMed ID: 22315058
[TBL] [Abstract][Full Text] [Related]
36. Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma.
Kono M; Komatsuda H; Yamaki H; Kumai T; Hayashi R; Wakisaka R; Nagato T; Ohkuri T; Kosaka A; Ohara K; Kishibe K; Takahara M; Katada A; Hayashi T; Kobayashi H; Harabuchi Y
Oncoimmunology; 2022; 11(1):2021619. PubMed ID: 35003900
[TBL] [Abstract][Full Text] [Related]
37. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
Brand TM; Iida M; Stein AP; Corrigan KL; Braverman CM; Coan JP; Pearson HE; Bahrar H; Fowler TL; Bednarz BP; Saha S; Yang D; Gill PS; Lingen MW; Saloura V; Villaflor VM; Salgia R; Kimple RJ; Wheeler DL
Clin Cancer Res; 2015 Jun; 21(11):2601-12. PubMed ID: 25767293
[TBL] [Abstract][Full Text] [Related]
38. Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt.
Kuo SZ; Blair KJ; Rahimy E; Kiang A; Abhold E; Fan JB; Wang-Rodriguez J; Altuna X; Ongkeko WM
BMC Cancer; 2012 Nov; 12():556. PubMed ID: 23176396
[TBL] [Abstract][Full Text] [Related]
39. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
Raoof S; Mulford IJ; Frisco-Cabanos H; Nangia V; Timonina D; Labrot E; Hafeez N; Bilton SJ; Drier Y; Ji F; Greenberg M; Williams A; Kattermann K; Damon L; Sovath S; Rakiec DP; Korn JM; Ruddy DA; Benes CH; Hammerman PS; Piotrowska Z; Sequist LV; Niederst MJ; Barretina J; Engelman JA; Hata AN
Oncogene; 2019 Sep; 38(37):6399-6413. PubMed ID: 31324888
[TBL] [Abstract][Full Text] [Related]
40. [Cancer stem cell phenotypes and miRNA: therapeutic targets in head and neck squamous cell carcinoma].
Coordes A; Zhifeng S; Sangvatanakul V; Qian X; Lenarz M; Kaufmann AM; Albers AE
HNO; 2014 Dec; 62(12):867-72. PubMed ID: 25337967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
